Differences

This shows you the differences between two versions of the page.

--- home:publications [19.11.2019 10:46]
Juha Kekäläinen
+++ home:publications [09.12.2019 15:29]
Teemu Kuulasmaa [2019]
@@ Line 7: / Line 7: @@
 Karttunen, J.; Heiskanen, M.; Lipponen, A.; Poulsen, D.; Pitkänen, A. **Extracellular Vesicles as Diagnostics and Therapeutics for Structural Epilepsies**, Int. J. Mol. Sci. 2019, 20(6), 1259; https://doi.org/10.3390/ijms20061259
+Paananen, J; Fortino, V. **An omics perspective on drug target discovery platforms.**, Brief Bioinform. 2019 Nov 27. pii: bbz122. https://doi.org/10.1093/bib/bbz122.
 Failli M, Paananen J, Fortino V. **Prioritizing target-disease associations with novel safety and efficacy scoring methods**, //Sci Rep// 2019, https://doi.org/10.1038/s41598-019-46293-7
-Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J, **Varanto: variant enrichment analysis and annotation**, Bioinformatics 2019, https://doi.org/10.1093/bioinformatics/btz046
+Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J. **Varanto: variant enrichment analysis and annotation**, Bioinformatics 2019, https://doi.org/10.1093/bioinformatics/btz046
-Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane XE, Levonen AL, Pitkänen A, **In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury—Lessons Learned**, //Int. J. Mol. Sci.// 2019, https://doi.org/10.3390/ijms20215395
+Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane XE, Levonen AL, Pitkänen A. **In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury—Lessons Learned**, //Int. J. Mol. Sci.// 2019, https://doi.org/10.3390/ijms20215395
-Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg K, Lohi O, Nykter M, Heinäniemi M: **Hemap: An interactive online resource for characterizing molecular phenotypes across hematologic malignancies**, //Cancer Research// 2019, https://doi.org/10.1158/0008-5472.CAN-18-2970
+Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg K, Lohi O, Nykter M, Heinäniemi M. **Hemap: An interactive online resource for characterizing molecular phenotypes across hematologic malignancies**, //Cancer Research// 2019, https://doi.org/10.1158/0008-5472.CAN-18-2970
 Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**,
 //Nucleic Acids Research// 2019, https://doi.org/10.1093/nar/gkz281
+Ngo Trong T, Mehtonen J, González G, Kramer R, Hautamäki V, Heinäniemi M. **Semisupervised Generative Autoencoder for Single-Cell Data.**, //J Comput Biol.// 2019, https://doi.org/10.1089/cmb.2019.0337
+Nikkilä A, Arvela H, Mehtonen J, Raitanen J, Heinäniemi M, Lohi O, Auvinen A. **Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia.**, //Scand J Work Environ Health.// 2019, https://doi.org/10.5271/sjweh.3867
+Sallinen H, Janhonen S, Pölönen P, Niskanen H, Liu OH, Kivelä A, Hartikainen JM, Anttila M, Heinäniemi M, Ylä-Herttuala S, Kaikkonen MU. **Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.**,  //BMC Cancer.// 2019 Nov 19, https://doi.org/10.1186/s12885-019-6339-0
+Pölönen P, Jawahar Deen A, Leinonen HM, Jyrkkänen HK, Kuosmanen S, Mononen M, Jain A, Tuomainen T, Pasonen-Seppänen S, Hartikainen JM, Mannermaa A, Nykter M, Tavi P, Johansen T, Heinäniemi M, Levonen AL. **Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma.**,
+//Oncogene.// 2019, https://doi.org/10.1038/s41388-019-0956-6
+Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA. **Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.**, //Haematologica.// 2019, https://doi.org/10.3324/haematol.2018.214882.
+Benhammou JN, Ko A, Alvarez M, Kaikkonen MU, Rankin C, Garske KM, Padua D, Bhagat Y, Kaminska D, Kärjä V, Pihlajamäki J, Pisegna JR, Pajukanta P. **Novel Lipid Long Intervening Noncoding RNA, Oligodendrocyte Maturation-Associated Long Intergenic Noncoding RNA, Regulates the Liver Steatosis Gene Stearoyl-Coenzyme A Desaturase As an Enhancer RNA.**
+//Hepatol Commun.// 2019 Aug 14, https://doi.org/10.1002/hep4.1413
+Jauhiainen S, Laakkonen JP, Ketola K, Toivanen PI, Nieminen T, Ninchoji T, Levonen AL, Kaikkonen MU, Ylä-Herttuala S.
+ **Axon Guidance-Related Factor FLRT3 Regulates VEGF-Signaling and Endothelial Cell Function.**, //Front Physiol.// 2019 Mar 12, https://doi.org/10.3389/fphys.2019.00224
+Viiri LE, Rantapero T, Kiamehr M, Alexanova A, Oittinen M, Viiri K, Niskanen H, Nykter M, Kaikkonen MU, Aalto-Setälä K. **Extensive reprogramming of the nascent transcriptome during iPSC to hepatocyte differentiation.**, //Sci Rep.//,
+Mar 5, https://doi.org/10.1038/s41598-019-39215-0
+Gurzeler E, Aavik E, Laine A, Valkama T, Niskanen H, Huusko J, Kaikkonen MU, Ylä-Herttuala S. **Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor.**, //Biochim Biophys Acta Gen Subj.//, 2019 Feb, https://doi.org/10.1016/j.bbagen.2018.11.012

Bioinformatics Center

User Tools

Site Tools

Differences

Page Tools